Roche's RoActemra gets EU label extension for damage prevention
This article was originally published in Scrip
Executive Summary
The EU's CHMP has supported an extension of indication of Roche's first-in-class interleukin-6 (IL-6) inhibitor RoActemra (tocilizumab; also known as Actemra) to include the reduction of rate of progression of joint damage and improvement of physical function in adults with moderately to severely active rheumatoid arthritis (RA) when given in combination with methotrexate.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.